Related by context. Frequent words. (Click for all words.) 71 Clinical Trial Results 70 Patient Enrollment 70 Cholesterol Drug 69 Presents Positive 67 Phase III Trial 66 Phase III Clinical Trial 66 Pivotal Study 65 Initiates Phase II 65 Achieves Milestone 65 Explore Strategic Alternatives 65 Announces FDA Clearance 65 Prostate Cancer Patients 64 Gastric Cancer 64 Announces Publication 64 Small Molecule 64 Pulmonary Arterial Hypertension 64 Single Dose 64 Patient Outcomes 63 Pivotal Trial 63 Transcept Pharmaceuticals 62 Inc Therapeutic Competitors 62 Well Tolerated 62 Commences Phase 62 Pivotal Phase III 62 Generic Version 62 CFO Resigns 61 Licensing Agreements 61 Cancer Vaccines 61 OSI Pharma 61 Study Indicates 61 Antifungal 61 Secures Financing 61 Announces Initiation 61 Advanced Prostate Cancer 61 Updates Guidance 61 Extends Tender Offer 61 Flu Vaccines 61 Patent Issued 61 Organizational Changes 60 Progenics Pharmaceuticals 60 Jury Verdict 60 Completes Tender Offer 60 IrelandRESEARCH AND MARKETS 60 Innovative Approach 60 Share Repurchases 60 Emisphere Technologies 60 Files Shelf Registration Statement 60 Opns 60 Heart Failure Patients 60 Inovio Pharmaceuticals 60 Drug Interactions 60 Stock Soars 60 Pivotal Phase 60 Q1 Loss Narrows 60 Provides Guidance 60 ACADIA Pharmaceuticals 60 Boceprevir 60 Technol 59 Issues Guidance 59 Benign Prostatic Hyperplasia 59 Targeted Therapy 59 Cyclacel Pharmaceuticals 59 Successful Completion 59 Adverse Reactions 59 Atopic Dermatitis 59 Delays Filing 59 Brain Cells 59 Recombinant Human 59 Cost Reductions 59 Momentum Continues 59 Lexicon Pharmaceuticals 58 BioDelivery Sciences 58 Summarizes 58 Patent Infringement Lawsuit 58 Onyx Pharma 58 Biomaterial 58 Dyslipidemia 58 Organizational Structure 58 Cardiovascular Events 58 Exploit collaboration 58 4Q Loss Narrows 58 Idenix Pharmaceuticals 58 Cuts Costs 58 Extends Offer 58 Announces Stockholder Approval 58 Valsartan 58 Overactive Bladder 58 Small Molecules 58 AVEO Pharmaceuticals 58 Sees Positive 58 Neogenix Oncology 58 Sixth Consecutive Year 57 1Q Loss Widens 57 Workforce Reduction 57 Stock Buyback 57 Signs Agreements 57 &Amp; 57 Medication Errors 57 Idera Pharmaceuticals 57 MLNM 57 Metabasis Therapeutics